Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study

• Main Authors: Kim Kab-Choong (Author), Yook Jeong-Hwan (Author), Eisenbraun Jürgen (Author), Kim Byung-Sik (Author), Huber Roman (Author)
• Format: Book
• Published: BMC, 2012-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/1472-6882-12-172; 1472-6882
• Keywords: Qol; EORTC QLQ-C30; QLQ-STO22; 5-FU; Viscum album; Other systems of medicine; RZ201-999
• Source: BMC Complementary and Alternative Medicine, Vol 12, Iss 1, p 172 (2012)

<p>Abstract</p> <p>Background</p> <p>Mistletoe (Viscum album L.) extracts are widely used in complementary cancer therapy. Aim of this study was to evaluate safety and efficacy of a standardized mistletoe extract (abnobaVISCUM® Quercus, aVQ) in patients with gastric cancer.</p> <p>Patients and Methods</p> <p>32 operated gastric cancer patients (stage Ib or II) who were waiting for oral chemotherapy with the 5-FU prodrug doxifluridine were randomized 1:1 to receive additional therapy with aVQ or no additional therapy. aVQ was injected subcutaneously three times per week from postoperative day 7 to week 24 in increasing doses. EORTC QLQ-C30 and -STO22 Quality of Life questionnaire, differential blood count, liver function tests, various cytokine levels (tumor necrosis factor (TNF)-alpha, interleukin (IL)-2), CD 16⁺/CD56⁺ and CD 19⁺ lymphocytes were analyzed at baseline and 8, 16 and 24 weeks later.</p> <p>Results</p> <p>Global health status (p <0.01), leukocyte- and eosinophil counts (p ≤0.01) increased significantly in the treatment group compared to the control group. Diarrhea was less frequently reported (7% vs. 50%, p=0.014) in the intervention group. There was no significant treatment effect on levels of TNF-alpha, IL-2, CD16⁺/CD56⁺ and CD 19⁺ lymphocytes and liver function tests measured by ANOVA.</p> <p>Conclusion</p> <p>Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer patients. ClinicalTrials.Gov Registration number NCT01401075.</p>